Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Baxter
Merck
Dow
AstraZeneca

Last Updated: December 5, 2019

DrugPatentWatch Database Preview

Patent: 8,933,205

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,933,205
Title:Process for preparing purified drug conjugates
Abstract: The invention provides a process for preparing a cell-binding agent chemically coupled to a drug. The process comprises covalently attaching a linker to a cell-binding agent, a purification step, conjugating a drug to the cell-binding agent and a subsequent purification step.
Inventor(s): Dai; Yong (Newton, MA), Wang; Yong (North Attleboro, MA), Jin; Shengjin (Acton, MA), Meshulam; Deborah H. (Brookline, MA), Amphlett; Godfrey W. (Cambridge, MA)
Assignee: ImmunoGen, Inc. (Waltham, MA)
Application Number:13/776,097
Patent Claims:see list of patent claims

Details for Patent 8,933,205

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial ImmunoGen, Inc. (Waltham, MA) 2025-08-24 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial ImmunoGen, Inc. (Waltham, MA) 2025-08-24 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial ImmunoGen, Inc. (Waltham, MA) 2025-08-24 RX Orphan search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial ImmunoGen, Inc. (Waltham, MA) 2025-08-24 RX Orphan search
Genentech RITUXAN rituximab VIAL 103705 001 1997-11-26   Start Trial ImmunoGen, Inc. (Waltham, MA) 2025-08-24 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 8,933,205

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Merck
Express Scripts
McKinsey
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.